TuHURA Biosciences (HURA) Net Income towards Common Stockholders (2010 - 2026)

TuHURA Biosciences' Net Income towards Common Stockholders history runs 15 years deep, the most recent figure standing at -$7.5 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 13.08% year-over-year to -$7.5 million in Q1 2026; TTM through Mar 2026 was -$30.9 million, a 7.46% increase from a year earlier, with the FY2025 full-year figure at -$30.1 million, down 32.72% from the prior year.
• Net Income towards Common Stockholders declined to -$7.5 million in Q1 2026 per HURA's latest filing, from -$6.8 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $4.7 million in Q2 2023 and bottomed at -$16.7 million in Q3 2024.
• The 5-year median for Net Income towards Common Stockholders is -$5.8 million (2022), against an average of -$5.6 million.
• Across the five-year window, Net Income towards Common Stockholders surged 233300.0% in 2023 and tumbled 430.82% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$3.5 million in 2022, then retreated by 20.43% to -$4.2 million in 2023, then sank by 300.09% to -$16.7 million in 2024, then surged by 59.38% to -$6.8 million in 2025, then decreased by 11.46% to -$7.5 million in 2026.
• Per Business Quant, the three latest HURA Net Income towards Common Stockholders figures stand at -$7.5 million (Q1 2026), -$6.8 million (Q4 2025), and -$7.1 million (Q3 2025).